Comparison · Updated
BPC-157 VS GHK-Cu
Short answer
GHK-Cu has stronger published evidence than BPC-157: tier B (Small human studies) vs tier C (Animal data).
Neither BPC-157 nor GHK-Cu is FDA-approved.
Both are prohibited in sport by WADA under section S0.
01
Side by side
| Field | BPC-157 | GHK-Cu |
|---|---|---|
| Evidence tier | C Tier C · Animal data | B Tier B · Small human studies |
| Tier rationale | Evidence is predominantly from rodent studies; human data are limited to a small retrospective pilot report, and a registered phase 1 trial posted no results. | Human data consist of small topical cosmetic/skin studies; most mechanistic evidence is in vitro and animal. |
| FDA status | Not approvedFDA has flagged BPC-157 as a bulk substance with potential safety risks for compounding. | Not approvedUsed as a cosmetic ingredient; not an approved drug. |
| Other approvals | None listed | None listed |
| WADA | Prohibited · S0Non-approved substances | Prohibited · S0Non-approved substances |
| Family | Repair | Repair |
| Residues | Not on file | Not on file |
| Molecular weight | Not on file | Not on file |
| Formula | Not on file | Not on file |
| Discovered | Not on file | 1973GHK identified in human plasma by Loren Pickart. |
| Routes studied | Subcutaneous, Intramuscular | Subcutaneous, Topical, Intramuscular |
| Mechanism | BPC-157 activates the FAK-paxillin pathway and upregulates VEGFR2 expression, promoting angiogenesis and accelerating tendon-to-bone healing. It modulates the nitric oxide (NO) system and has cytoprotective effects on the gastrointestinal mucosa through interaction with the dopamine and serotonin systems. | GHK-Cu chelates copper(II) ions and delivers them to tissues, activating metalloproteinases that remodel the extracellular matrix. It stimulates collagen I, III, and V synthesis, promotes decorin and glycosaminoglycan production, and upregulates DNA repair genes while suppressing pro-inflammatory cytokines like TGF-beta. |
| Safety notes | Generally well-tolerated in animal studies with a wide therapeutic window. | Well-tolerated both topically and via injection with decades of cosmetic use. |
| Cited studies | 0 studies | 0 studies |
02
Questions
- Which has stronger evidence, BPC-157 or GHK-Cu?
- GHK-Cu has stronger published evidence than BPC-157: tier B (Small human studies) vs tier C (Animal data). BPC-157: Evidence is predominantly from rodent studies; human data are limited to a small retrospective pilot report, and a registered phase 1 trial posted no results. GHK-Cu: Human data consist of small topical cosmetic/skin studies; most mechanistic evidence is in vitro and animal. Tiers rate the strength of published evidence, not effectiveness.
- Is BPC-157 FDA-approved?
- BPC-157 is not FDA-approved. FDA has flagged BPC-157 as a bulk substance with potential safety risks for compounding.
- Is GHK-Cu FDA-approved?
- GHK-Cu is not FDA-approved. Used as a cosmetic ingredient; not an approved drug.
- Are BPC-157 and GHK-Cu banned in sport?
- Both are prohibited in sport by WADA under section S0.
- How do BPC-157 and GHK-Cu work?
- BPC-157 activates the FAK-paxillin pathway and upregulates VEGFR2 expression, promoting angiogenesis and accelerating tendon-to-bone healing. GHK-Cu chelates copper(II) ions and delivers them to tissues, activating metalloproteinases that remodel the extracellular matrix.